Practitioner Information


Genostics Cancer Seminar:

Personalised and targeted medicine: From Screening to Tumour Profiling


The seminar focuses on current options for personalised diagnostics, treatment strategies, and the effective monitoring of a person's cancer status in real time. You'll meet world renowned scientists and practitioners who are forging the future of personalised cancer management.  Nutritious lunch and snacks will be provided.

Careful consideration of the complete tumor context is essential to understanding and developing more effective personalized treatments that address tumor heterogeneity
— Zellmer and Zhang (2014), "Evolving concepts of tumor heterogeneity," Cell Biosci. 2014; 4: 69

The future of personalised oncology is now. The network of Oncologists and practitioners who are applying novel technologies to assist in personalised cancer management is rapidly expanding. The use of personalised treatment design is allowing better patient outcomes.

The seminar will include updates on the latest in personalised diagnostic technology and how it is revolutionising cancer management. Presentations in cancer diagnosis and monitoring will include liquid biopsy, molecular profiling, immune/toxicity panels and epigenetics. Treatment strategies presented will focus on the prevention of metastasis, recovery from cytotoxic therapies, immune and complementary therapies and a review of current Integrative Oncology Clinics. Case studies will be discussed and the seminar will be a great chance to meet and discuss personalised cancer treatment with colleagues.



  • Liquid Biopsy with focus on Maintrac CTC
  • Tumour Profiling with focus on OncoDNA
  • Monitoring treatment progress and risk of progression, liquid biopsies
  • Measuring contributing factors. Immune Panels, Toxicity Panels
  • Methylation, current status of testing, DNA methylation


  • Prevention strategies
  • Integrative Primary Treatment
  • Recovery following cytotoxic therapies
  • 2nd prevention strategies
  • How to use Botanicals and Nutrients
  • Review of specific therapies, including IV nutrients and botanicals
  • Immune Therapies including pd-L1 inhibitors, Dendritic Cell Vaccines, NK
  • therapies, p53 Gene Therapies, GcMAF
  • Biophysical Therapies incl Hyperthermia, Laser Therapies
  • Integrative Oncology Clinics Review

Subject to change

Prof. Katharina Pachmann

Prof Haslberger

A/Prof David Bell

Dr. Al-Housami

Dr. Peter Eng

Dr. Sandeep Gupta


Click to view program. N.B. Subject to change without notice

What you can expect

Discover which clinically validated, accredited options are available for clinical use, and become updated in novel technologies to look out for as the options evolve.

Understand which diagnostic options are appropriatefor which patient at what time.

Learn how to design cancer treatment and how to best monitor the success of therapy. This includes a discussion on the practical selection of available technologies and strategies, report analysis and case-studies brought by both presenters and attendees.

These seminars offer practitioners a unique opportunity to meet and discuss personalised cancer management with scientific and clinical experts, become up-to-date in the latest scientific developments in the field and know your options when it comes to personalising cancer management for better patient outcomes.


  • Saturday 22nd and Sunday 23rd September
  • Attendance one or both days available
  • Nutritious lunch & snacks provided both days
  • Sydney CBD venue to be confirmed

One day (Saturday 22nd Sept only): AU$295

Both days (Saturday 22nd and Sunday 23rd Sept): AU$395


December Seminar

December Seminar

CTC Seminar:

Monitoring the effectiveness of cancer treatment

A joint-seminar with Dr. Katherina Pachmann and Dr. Fluhrer

Practitioners are invited to join practitioners at the Genostics CTC Seminar designed to bring you the latest information on how to monitor the effectiveness of cancer treatment, presented by world-renowned CTC scientist Prof. Katherina PachmannThe Seminar

Circulating Tumour Cells (CTCs) are the metastasising population of cancer cells. CTCs are now well established as independent prognostic indicators of metastatic disease. CTC enumeration and analysis represents a 'fluid-biopsy,' with results now firmly associated with clinical outcome. Practitioners and Oncologists who are interested or are already benefiting from using CTC-tests will be in attendance.

Prof. Katherina Pachmann is a world-renowned expert in Circulating Tumour Cell science - both in research and in translational medicine. She has worked internationally in academically and scientifically acclaimed cell research centers. She will be presenting new research at COSA and the World Cancer Congress in November in Melbourne, as well as presenting seminars to practitioners in locations around Australia and New Zealand.

Dr. Joachim Fluhrer has recently been acknowledged internationally for Excellence in Integrative Medicine, and will be touring alongside Prof. Pachmann. Dr. Fluhrer brings his clinical and medical expertise to the discussion table, and is passionate about facilitating the best in evidence-based medical research for use in the clinical setting.

This seminar will be a unique opportunity to meet CTC expert scientist Prof. Pachmann and discuss clinical cases you might have with her and Dr. Fluhrer together. The seminar will include updates on the latest in CTC-technology and how it is revolutionising cancer monitoring, and will be a great chance to meet and discuss personalised cancer treatment with colleagues.

CTC Characterisation is expected to contribute to guiding specific targeted therapies to a defined population of cancer patients within a certain therapeutic window - which is the hallmark of personalized medicine
— Alix-Panabieres & Pantel, Clinical Chemistry 2014, 59(1): 110-8

More info.. Professor Pachmann has concentrated her research career on the detection, identification, and treatment of cancer cells in the peripheral blood. Professor Pachmann has worked in cell research internationally in academically and scientifically acclaimed centres such as Karolinka Insitute Stockholm, Sweden; Institute of Hematology,GSF Munich, Germany; MD Anderson Cancer Centre Houston, Texas.


Presently Professor Pachmann has her laboratory at the Klinik fur Innere Medizin II Fredrich-Schiller Universitat in Germany, where she holds Professorship Experimental Hematology and Oncology. Professor Pachmann has numerous publications in world renowned journals of Hematology, Clinical Oncology, Surgical Oncology and Cancer Research.


CTC Webinar Series

Presented by Dr Joachim Fluhrer

Level I: (Completed)
Metastatic biology, Circulating Tumour Cells and personalised cancer management

Level II: (Completed)
In the clinic: monitoring treatment effectiveness and metastatic risk, CTC test selection and report interpretation

Level III: (Completed)
Clinical Case Discussions: practitioner presentations